Compare Amgen, Inc. (AMGN) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while State Street Technology Select Sector SPDR ETF trades at $183.14. The key difference: Amgen, Inc. pays a 2.77% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals.
| AMGN | XLK | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $198.21 |
52-Week Low | $271.18 | $127.49 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
XLK, the Technology Select Sector SPDR ETF, trades at $185.79, up 0.24% today, with a bullish technical signal driven by moving averages. It has gained 33% year-to-date as of July 2026, outperforming the Nasdaq-100, supported by strong tech earnings and sector inflows. A dividend of $0.23 is scheduled for June 2026.
The outlook remains positive given robust tech fundamentals and institutional optimism, but risks include market concentration, Fed policy shifts, and potential valuation pressures. Wall Street sentiment is bullish, though some investors are reducing mega-cap tech exposure ahead of key guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
